Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
DIOVAN HCT 160mg/12.5mg |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker + diuretic. |
| Generic Name |
|
Valsartan 160mg, hydrochlorothiazide 12.5mg; tabs. |
| Also |
• DIOVAN HCT 160mg/25mg
• DIOVAN HCT 320mg/12.5mg
• DIOVAN HCT 320mg/25mg
• DIOVAN HCT 80mg/12.5mg
|
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Take once daily. Add-on or initial therapy and not volume-depleted: Initially 160mg/12.5mg; may increase after 1–2 weeks up to max 320mg/25mg. Replacement therapy: may be substituted for the titrated components. Maximum effects within 2–4 weeks after dose change. CrCl ≤30mL/min: not recommended. |
| Contraindications |
|
Anuria. Sulfonamide allergy. |
| Precautions |
|
Intravascular volume depletion; do not use as initial therapy. Correct salt/volume depletion before starting, or monitor closely. Hepatic or severe renal impairment. Arrhythmias. Postsympathectomy. Diabetes. Gout. Asthma. Severe CHF. Renal artery stenosis. SLE. Monitor electrolytes. Pregnancy (Cat.D; avoid in 2nd and 3rd trimesters). Nursing mothers: not recommended. |
| Interactions |
|
Monitor for hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH. Antagonized by NSAIDs, cholestyramine, colestipol resins. Orthostatic hypotension may be potentiated by alcohol, barbiturates, narcotics, antihypertensives. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. Adjust antidiabetic, antigout medications. Avoid lithium. May increase toxicity of digitalis, lithium. May interfere with parathyroid tests. |
| Adverse Reactions |
|
Headache, dizziness, nasopharyngitis, viral infection, fatigue, cough, diarrhea, orthostatic hypotension, electrolyte disturbances (eg, hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, increased serum cholesterol or triglycerides; rare: rhabdomyolysis. |
| How Supplied |
|
Tabs—90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
